Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company, announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported collaboration revenue of $2.8 million for Q4 2025, a decrease from $60.6 million in Q4 2024, but an increase in total collaboration revenue for the year to $123.7 million compared to $75.6 million in 2024. The net loss for Q4 2025 was $46.1 million, compared to $13.4 million in the same quarter of the previous year. Despite the losses, Monte Rosa's cash position remains strong, with $382.1 million in cash and equivalents as of December 31, 2025, down from $396.2 million at the end of Q3 2025. The decrease was attributed to operational cash use, partially offset by proceeds from stock sales. The company successfully closed a $345 million public offering in January 2026, enhancing its financial runway into 2029. Monte Rosa highlighted significant clinical advancements, including positive interim data from its NEK7-directed MGD MRT-8102, which demonstrated substantial reductions in CRP levels in patients with elevated cardiovascular disease risk. The company plans to initiate multiple Phase 2 studies for MRT-8102 in various indications, including chronic kidney disease and gout flares, in the coming years. Additionally, Monte Rosa is advancing its VAV1-directed MGD MRT-6160 in collaboration with Novartis, with multiple Phase 2 studies anticipated to begin in 2026. The company also reported promising interim data from its MRT-2359 program in metastatic castration-resistant prostate cancer, with plans for a Phase 2 study in combination with apalutamide expected to start in Q3 2026. Overall, Monte Rosa's strategic initiatives and strong financial position position it well for future growth and clinical advancements.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.